166 related articles for article (PubMed ID: 29066038)
21. Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series.
Thamer M; Zhang Y; Lai D; Kshirsagar O; Cotter D
BMC Nephrol; 2013 Aug; 14():172. PubMed ID: 23927675
[TBL] [Abstract][Full Text] [Related]
22. Health Canada Warning on Citalopram and Escitalopram--Its Effects on Prescribing in Consultation-Liaison Psychiatry.
Do A; Noohi S; Elie D; Mahdanian AA; Yu C; Segal M; Looper KJ; Rej S
Psychosomatics; 2016; 57(1):57-63. PubMed ID: 26633294
[TBL] [Abstract][Full Text] [Related]
23. Persisting decline in depression treatment after FDA warnings.
Libby AM; Orton HD; Valuck RJ
Arch Gen Psychiatry; 2009 Jun; 66(6):633-9. PubMed ID: 19487628
[TBL] [Abstract][Full Text] [Related]
24. [Citalopram and QT prolongation].
Alušík Š; Paluch Z
Vnitr Lek; 2018; 63(12):952-956. PubMed ID: 29334745
[TBL] [Abstract][Full Text] [Related]
25. Effect of the FDA Black Box Suicidality Warnings for Antidepressants on Suicide Rates in the USA.
Plöderl M; Hengartner MP
Crisis; 2023 Mar; 44(2):128-134. PubMed ID: 34915730
[No Abstract] [Full Text] [Related]
26. A comparison of the risk of QT prolongation among SSRIs.
Funk KA; Bostwick JR
Ann Pharmacother; 2013 Oct; 47(10):1330-41. PubMed ID: 24259697
[TBL] [Abstract][Full Text] [Related]
27. FDA drug safety communications: a narrative review and clinical considerations for older adults.
Marcum ZA; Vande Griend JP; Linnebur SA
Am J Geriatr Pharmacother; 2012 Aug; 10(4):264-71. PubMed ID: 22683398
[TBL] [Abstract][Full Text] [Related]
28. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Crépeau-Gendron G; Brown HK; Shorey C; Madan R; Szabuniewicz C; Koh S; Veinish S; Mah L
J Affect Disord; 2019 May; 250():341-345. PubMed ID: 30877856
[TBL] [Abstract][Full Text] [Related]
29. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.
Nemeroff CB; Kalali A; Keller MB; Charney DS; Lenderts SE; Cascade EF; Stephenson H; Schatzberg AF
Arch Gen Psychiatry; 2007 Apr; 64(4):466-72. PubMed ID: 17404123
[TBL] [Abstract][Full Text] [Related]
30. Outpatient Fluoroquinolone Prescription Fills in the United States, 2014 to 2020: Assessing the Impact of Food and Drug Administration Safety Warnings.
Buehrle DJ; Wagener MM; Clancy CJ
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0015121. PubMed ID: 33875430
[TBL] [Abstract][Full Text] [Related]
31. National antidepressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning.
Mittal M; Harrison DL; Miller MJ; Brahm NC
Res Social Adm Pharm; 2014; 10(5):781-90. PubMed ID: 24355381
[TBL] [Abstract][Full Text] [Related]
32. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK.
Murray ML; Thompson M; Santosh PJ; Wong IC
Drug Saf; 2005; 28(12):1151-7. PubMed ID: 16329717
[TBL] [Abstract][Full Text] [Related]
33. Use of Antidepressants in Older People during a 10-Year Period: An Observational Study on Prescribed Doses and Serum Levels.
Tveit K; Hermann M; Waade RB; Nilsen RM; Wallerstedt SM; Molden E
Drugs Aging; 2020 Sep; 37(9):691-701. PubMed ID: 32691329
[TBL] [Abstract][Full Text] [Related]
34. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S; Leslie DL; Rosenheck RA
J Clin Psychiatry; 2009 Jun; 70(6):906-12. PubMed ID: 19422760
[TBL] [Abstract][Full Text] [Related]
35. Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders.
Gupta S; Gersing KR; Erkanli A; Burt T
Psychiatr Q; 2016 Jun; 87(2):329-42. PubMed ID: 26303613
[TBL] [Abstract][Full Text] [Related]
36. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns?
Busch SH; Frank RG; Leslie DL; Martin A; Rosenheck RA; Martin EG; Barry CL
Psychiatr Serv; 2010 Jan; 61(1):11-6. PubMed ID: 20044412
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Citalopram Dosage Risk Mitigation in a Veteran Population.
Rector TS; Adabag S; Cunningham F; Nelson D; Dieperink E
Am J Psychiatry; 2016 Sep; 173(9):896-902. PubMed ID: 27166093
[TBL] [Abstract][Full Text] [Related]
38. Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning.
Cook BL; Wang Y; Sonik R; Busch S; Carson N; Progovac AM; Zaslavsky AM
Health Serv Res; 2019 Feb; 54 Suppl 1(Suppl 1):255-262. PubMed ID: 30666633
[TBL] [Abstract][Full Text] [Related]
39. A critical evaluation of the cardiac toxicity of citalopram: part 1.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Nov; 49(11):13-6. PubMed ID: 22007855
[TBL] [Abstract][Full Text] [Related]
40. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
Chastang A; Renet S; Corny J; Beaussier H; Petre A; Lillo-Lelouet A; Phan Thi TT; Bézie Y
Int J Clin Pharm; 2019 Feb; 41(1):42-48. PubMed ID: 30610545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
